非布索坦如何使用？

The tablet is a 2-arylthiazole derivative, a new, highly effective, non-purine selective inhibitor of xanthine oxidase. It reduces blood uric acid concentration by inhibiting the production of uric acid, and is suitable for the treatment of hyperuricemia in patients with gout. Adverse reactions of febuxostat: Mild liver enzyme elevations and a rare incidence of serious cardiovascular events. It is contraindicated in patients with ischemic heart disease and congestive heart failure. Today we will learn about how to use febuxostat?

The oral dose of febuxostat is 40 mg or 80 mg, starting with a low dose of 40 mg once daily. If the blood uric acid level is still 360umol/L after two weeks, it can be increased to 80mg, once a day.

Febuxostat was started at 10 mg/day for 2 weeks, then increased to 20 mg/day for 4 weeks, then to 40 mg/day. Starting with a low dose and gradually increasing the dose can prevent acute gout attacks caused by initial changes in blood uric acid levels. Treat with febuxostat 40 mg/day for 6 months, and review uric acid levels regularly. Generally, it takes 6 months to clean up excess blood uric acid in the body. 

After 6 months of treatment: (1) If the blood uric acid level remains between 240 umol/l and 360 umol/l, maintain febuxostat 40 mg/day treatment. (2) If the blood uric acid level is higher than 360 umol/l, increase the dose of fexostatin by 60 mg/day, up to a maximum of 80 mg/day, and monitor blood uric acid, liver and kidney function regularly. (3) If the blood uric acid level is lower than 240 umol/l, the dose of febuxostat can be reduced to 20 mg/day and the treatment can be maintained for 6 months.

In February 2009, the U.S. Food and Drug Administration approved febuxostat for the long-term treatment of patients with gout and hyperuricemia. Indications of Febuxostat: Febuxostat is a Class A recommendation for the drug treatment of patients with hyperuricemia and gout, which is the first-line drug choice. However, it is not recommended for use in asymptomatic hyperuricemia.

Febuxostat has obvious advantages over allopurine:

(1) Allopurinol only inhibits the reduced form of XOR, while febuxostat has a significant inhibitory effect on both oxidized and reduced forms of XOR, so its uric acid-lowering effect is more powerful and lasting;

(2) Since allopurinol is a purine analogue, it will inevitably affect the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. Febuxostat is a non-purine XOR inhibitor and therefore has a better safety profile.

The above is the usage method, I hope it can help you!